AbbVie says EU approves Rinvoq for children with polyarticular juvenile idiopathic arthritis
ABBV•EU approves Rinvoq for pediatric polyarticular juvenile idiopathic arthritis
The European Commission cleared AbbVie’s Rinvoq for active polyarticular juvenile idiopathic arthritis in patients aged 2 and older.
Use targets children who failed or cannot tolerate at least one DMARD; dosing includes 15 mg tablets or weight-based oral solution.
The decision relied on the open-label Phase 1 SELECT-YOUTH pediatric study, supported by adult rheumatoid arthritis data.
